Global Antimicrobial Therapeutics Market - 2024-2031

Global Antimicrobial Therapeutics Market - 2024-2031

Global antimicrobial therapeutics market reached US$ YY million in 2023 and is expected to reach US$ YY million by 2031, growing at a CAGR of YY% during the forecast period 2024-2031.

Antimicrobial therapeutics refer to pharmaceutical drugs and treatments designed to combat infections caused by microorganisms such as bacteria, viruses, fungi and parasites. These therapeutics work by inhibiting the growth of or killing the microorganisms responsible for the infection, thereby helping the body to recover from the illness.

These therapeutics encompass a wide range of medications and treatment modalities, including antibiotics, antivirals, antifungals and antiparasitic drugs. Each type of antimicrobial agent targets specific types of microorganisms, and they may be administered through various routes such as oral ingestion, topical application, injection or infusion.

Market Dynamics: Drivers

Rising demand for novel therapeutics

The rising demand for novel therapeutics is expected to drive the antimicrobial therapeutics market over the forecast period. There are still different types of infectious diseases for which effective treatment options are limited or non-existent. This includes infections caused by multidrug-resistant bacteria, as well as emerging pathogens such as certain viruses and fungi. The demand for new antimicrobial therapeutics such as antiviral, antifungal and antibiotic drugs arises from the need to address these unmet medical needs and for also treating various viral and fungal infections.

For instance, on September 29, 2023, BDR Pharmaceutical launched Zisavel capsules for treating invasive aspergillosis and mucormycosis, both fungal infections. This generic medication, classified under azole antifungals, is offered at one-third of the price of the current therapy provided by the innovators. Zisavel capsules will be available as 100 mg capsules.

Major market players are focussing on accelerating the discovery and development of new antimicrobial drugs. This has led to an increasing number of candidate compounds in the drug development pipeline, driving the demand for novel therapeutics. For instance, on December 28, 2021, Cipla Limited cleared that the drug maker had been granted Emergency Use Authorisation (EUA) permission by the Drug Controller General of India (DCGI) for the launch of Molnupiravir in the country. Cipla plans to launch Molnupiravir under the brand name Cipmolnu. Molnupiravir is the first oral antiviral approved by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for the treatment of mild-to-moderate COVID-19 at high risk of developing severe disease.

Further, the increasing prevalence of various viral, fungal diseases and other infectious diseases, rising FDA and other regulatory approvals for novel drugs and increasing clinical trials to develop more therapeutics are the factors expected to drive the market over the forecast period.

Restraints

Factors such as complications and side effects associated with the various therapeutics, availability of alternative generic drugs, regulatory challenges associated with the various antimicrobial therapeutics and unmet needs are the factors expected to hamper the market.

Segment Analysis

The global antimicrobial therapeutics market is segmented based on drug class, application, route of administration, distribution channel and region.

The antibiotics segment accounted for approximately 54.3% of the antimicrobial therapeutics market share

The antibiotics segment is expected to hold the largest market share over the forecast period. Antibiotics have historically played a central role in the treatment of bacterial infections since the discovery of penicillin in the 1920s. The widespread use and success of antibiotics in treating bacterial diseases have established them as a cornerstone of modern medicine, leading to their widespread adoption and dominance in the antimicrobial therapeutics market.

Antibiotics exhibit a broad spectrum of activity against a wide range of bacterial pathogens, making them versatile agents for the treatment of various infectious diseases. Different classes of antibiotics target specific bacterial structures or metabolic pathways, allowing for targeted therapy against different types of bacteria. Thus, major market players are developing various antibiotics to treat various infections.

For instance, on January 30, 2023, Alkem launched an antibiotic to treat multiple drug-resistant infections. The firm became the first from India to launch a novel antibiotic combination for treating drug-resistant infections, the company claimed. The antibiotic, a combination of ceftazidime and avibactam, will be sold under the brand name Zidavi. It is indicated for various ailments such as complicated urinary tract infections.

Pharmaceutical companies and research institutions continue to invest in the discovery, performing clinical trials and development of new antibiotics to address emerging resistance and unmet medical needs. Advances in drug discovery technologies, such as high-throughput screening and structure-based design, have facilitated the identification of novel antibiotic candidates, driving innovation within the antibiotics segment.

For instance, in April 2023, GSK plc presented positive results from the pivotal EAGLE-2 and EAGLE-3 phase III trials for gepotidacin, an investigational, first-in-class oral antibiotic with a novel mechanism of action for uncomplicated urinary tract infections (uUTI) in female adults and adolescents. The data were disclosed in an oral presentation at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Denmark.

Further, in March 2024, Wockhardt cleared the results of the successful use of an investigational antibiotic under-trial drug, Zidebactam/Cefepime, to treat a highly drug-resistant skull bone infection and pneumonia in a renal transplant patient. The case involved a 62-year-old man who suffered from sino-pulmonary infection and skull base osteomyelitis (a disease with a high risk of complications including neuro-infection) caused by NDM-producing Pseudomonas aeruginosa.

Geographical Analysis

North America accounted for approximately 41.4% of the market share

North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and rising FDA approvals for antimicrobial therapeutics in the region. North America especially the United States is home to several leading pharmaceutical companies that are actively engaged in the development, manufacturing and commercialization of antimicrobial therapeutics. These companies have established a strong presence in the region, leveraging their expertise in developing various antimicrobial therapeutics to drive innovation and market expansion.

For instance, in October 2020, Gilead Sciences, Inc. cleared the U.S. Food and Drug Administration (FDA) approval for the antiviral drug Veklury (remdesivir) for the treatment of patients with COVID-19 requiring hospitalization. As an antiviral drug, Veklury works to stop the replication of SARS-CoV-2, the virus that causes COVID-19. Previously authorized by the FDA for emergency use to treat COVID-19, Veklury is now the first and only approved COVID-19 treatment in the United States.

Additionally, on May 3, 2024, Dr. Reddy’s Laboratories Ltd. launched Doxycycline Capsules, 40 mg in the U.S. market. It is a therapeutic generic equivalent of ORACEA (doxycycline, USP) Capsules, 40 mg approved by the U.S. Food and Drug Administration (USFDA). It is a broad-spectrum antibiotic and it is used in the treatment of infections caused by bacteria and certain parasites. It is used to treat bacterial pneumonia, acne, chlamydia infections, Lyme disease, cholera, typhus and syphilis. It is also used to prevent malaria.

The U.S. Food and Drug Administration (FDA) plays a central role in the regulation and approval of antimicrobial drugs in the United States. In recent years, there has been a notable increase in FDA approvals for new antimicrobial therapeutics, including antibiotics, antivirals, antifungals and antiparasitic drugs. These approvals signal a growing pipeline of innovative drugs and therapies entering the market, further fueling market growth.

For instance, on May 25, 2023, the U.S. Food and Drug Administration approved the oral antiviral Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19, including hospitalization or death. Paxlovid is the fourth drug—and first oral antiviral pill—approved by the FDA to treat COVID-19 in adults.

Competitive Landscape

The major global players in the antimicrobial therapeutics market include Centrient Pharmaceuticals, Mayne Pharma, Galderma Laboratories, L.P., Pfizer Inc., Tetraphase Pharmaceuticals, Inc., Journey Medical Corporation, Paratek Pharmaceuticals, Inc., Crown Laboratories, Inc., ANI Pharmaceuticals, Inc. and Genentech, Inc. among others.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global antimicrobial therapeutics market. In response to the pandemic, there was increased awareness of the importance of antimicrobial therapeutics, especially antiviral drugs to prevent the emergence and spread of the COVID-19 virus. In some cases, healthcare providers became more cautious in prescribing antibiotics to COVID-19 patients, reducing the overall consumption of antimicrobial drugs. During the pandemic, there was a heightened demand for antiviral drugs and many market players focused on developing various antiviral drugs for the treatment of COVID-19.

For instance, on November 05, 2021, Pfizer Inc. cleared its investigational novel COVID-19 oral antiviral candidate, PAXLOVID, significantly reduced hospitalization and death, based on an interim analysis of the Phase 2/3 EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients) randomized, double-blind study of non-hospitalized adult patients with COVID-19, who are at high risk of progressing to severe illness.

Moreover, on July 28, 2022, Zenara Pharma, cleared approval from the Central Drugs Standard Control Organisation (CDSCO) to manufacture and sell COVID-19 antiviral pills. The drugmaker manufactured Nirmlatrelvir and Ritonavir combi pack — the combination of which is called Paxlovid. The tablet will then be sold under the brand name 'Paxzen'. The tablets and active pharmaceutical ingredients (APIs) will be 100 percent made in India.

Market Segmentation

By Drug Class
• Antibiotics
• Antivirals
• Antifungals
• Antiparasitic Drugs
• Others

By Application
• Respiratory Infections
• Urinary Tract Infections
• Gastrointestinal Infections
• Sexually Transmitted Infections
• Skin and Soft Tissue Infections
• Systemic Infections
• Others

By Route of Administration
• Oral
• Topical
• Intravenous
• Intramuscular
• Subcutaneous
• Intranasal
• Others

By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
• Middle East and Africa

Why Purchase the Report??
• To visualize the global antimicrobial therapeutics market segmentation based on drug class, application, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of antimicrobial therapeutics market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global antimicrobial therapeutics market report would provide approximately 69 tables, 77 figures and 197 Pages.

Target Audience 2024
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies